MedTrace Logo

Use of Armodafinil for Fatigue in Sarcoidosis

NCT00555347 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-05-27

No results posted yet for this study

Summary

To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.

Conditions

Interventions

DRUG

Armodafinil

Dosage 150-250 mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Cephalon

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P Baughman, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555347 on ClinicalTrials.gov